Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Accenture
Citi
Chubb
Fish and Richardson
US Department of Justice
UBS
McKesson
Federal Trade Commission

Generated: January 17, 2019

DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

Summary for Teva Pharm

Drugs and US Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms CEFDINIR cefdinir FOR SUSPENSION;ORAL 065332-002 May 4, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 RX Yes No 8,006,690 ➤ Try a Free Trial Y ➤ Try a Free Trial
Teva Pharms Usa CEFTRIAXONE ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 065227-002 Mar 15, 2007 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,620,847 ➤ Try a Free Trial
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 6,446,627 ➤ Try a Free Trial
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-001 Jan 27, 2017 6,446,627 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 2016-10-26
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 2008-08-11
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26
Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Supplementary Protection Certificates for Teva Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/022 United Kingdom ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF EFAVIRENZ, EMTRICITABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, AND TENOFOVIR OR A PHARMACEUTICALLY ACCEPTABLE PRODRUG, SALT OR ESTER THEREOF, PARTICULARLY TENOFOVIR DISOPROXIL, ESPECIALLY TENOFOVIR DISOPROXIL FUMARATE; REGISTERED: UK EU/1/07/430/001 20071213
/2005 Austria ➤ Try a Free Trial PRODUCT NAME: PALONOSETRON, DESSEN SALZE UND STEREOISOMERE; REGISTRATION NO/DATE: EU/1/04/306/001 20050322
2012000038 Germany ➤ Try a Free Trial PRODUCT NAME: KOMBINATION AUS RILPIVIRIN ODER EINER STEREOCHEMISCH ISOMEREN FORM ODER EINEM PHARMAZEUTISCH UNBEDENKLICHEN ADDITIONSSALZ DESSELBEN, EINSCHLIESSLICH DES CHLORWASSERSTOFFSAEURESALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT.; REGISTRATION NO/DATE: EU/1/11/737/001 20111128
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Citi
US Army
AstraZeneca
Queensland Health
Chinese Patent Office
Mallinckrodt
Fuji
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.